Bioscience

Biozona Weekly: Cancer drug approved; Bioscience potential; New biomedical campus projects

September 12, 2013

By Flinn Foundation

ASU spinout companies generate $68 million in funding
9/11/13 | Phoenix Business Journal | Hayley Ringle

Arizona State University spinout companies based on technologies developed by university researchers raised $68 million in external venture funding during the 2013 fiscal year.

Bioscience blather
9/11/13 | Arizona Republic | Opinion (Bob Robb)

Bioscience is a good industry that pays well and does good and important work, but it’s not the key to unlocking our economy from its illusionary “handcuffs” and isn’t really markedly more important than any other industry, including those without such illustrious champions.

Phoenix Biomedical Campus launching two new projects

9/10/13 | Phoenix Business Journal | Angela Gonzales

A 150,000-square-foot laboratory with office space and a new parking structure are in the works on the Phoenix Biomedical Campus, where construction is already underway on a $100 million outpatient cancer treatment clinic.

LabCorp to hire 100 in Phoenix
9/9/13 | Phoenix Business Journal | Angela Gonzales

Laboratory Corp. of America Holdings is looking to hire 100 Phoenix-area technicians over the next three months.

Unleashing the power of bioscience research
9/7/13 | Arizona Republic | Op-Ed (Greg Stanton, Michael Crow, Wyatt Decker)

The planned Arizona Biomedical Corridor and a renewed commitment to bioscience research and innovation is the road to a stronger and more sustainable economic future for the state.

Casa Verde may become STEM school
9/7/13 | Casa Grande Dispatch | Susan Randall

The Casa Grande Union High School District has been laying the groundwork to turn Casa Verde Charter High School into a STEM school with an advanced curriculum to challenge students with real world, hands-on applications of science and technology.

Cancer drug combo tested in metro Phoenix is OK’d
9/6/13 | Arizona Republic | Peter Corbett

A new drug combination tested in metro Phoenix to treat late-stage pancreatic cancer was approved by the U.S. Food and Drug Administration after showing the combination of Abraxane and gemcitabine helped 35 percent of patients live at least one year. Read also: FDA approves a drug for late-stage pancreatic cancer

Yuma Regional Cancer Center-Big Dreams Underway
9/6/13 | Yuma Sun | Joyce Lobeck

Excavation is now underway for the 40,000-square-foot Yuma Regional Cancer Center, a new state-of-the-art facility projected to open in May 2014.

Barber co-sponsoring act to fund technology transfer
9/6/13 | Inside Tucson Business | Staff Report

Arizona Congressman Ron Barber hopes to get federally-funded research and technology moved to the commercial marketplace more quickly by co-sponsoring the Technology and Research Accelerating National Security and Future Economic Resiliency (TRANSFER) Act.